Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Institutional and Insider Ownership
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Phathom Pharmaceuticals and Unicycive Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Phathom Pharmaceuticals | 1 | 1 | 6 | 1 | 2.78 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Profitability
This table compares Phathom Pharmaceuticals and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Phathom Pharmaceuticals | -41.34% | N/A | -20.81% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Valuation & Earnings
This table compares Phathom Pharmaceuticals and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Phathom Pharmaceuticals | $175.11 million | 3.46 | -$221.25 million | ($1.28) | -5.84 |
| Unicycive Therapeutics | $680,000.00 | 196.59 | -$26.56 million | ($1.75) | -2.74 |
Unicycive Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Phathom Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
Summary
Phathom Pharmaceuticals beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
